Edgewise Therapeutics EWTX
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Edgewise Therapeutics (EWTX) Business Model and Operations Summary
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
Key Insights
Edgewise Therapeutics (EWTX) Core Market Data and Business Metrics
Latest Closing Price
$20.13Market Cap
$1.93 BillionPrice-Earnings Ratio
-13.51Total Outstanding Shares
95.21 Million SharesTotal Employees
110Dividend
No dividendIPO Date
March 26, 2021SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
1715 38th St, Boulder, CO, 80301
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities, Continuing | $-178.59 Million |
| Net Cash Flow From Operating Activities, Continuing | $-108.90 Million |
| Net Cash Flow From Investing Activities | $-178.59 Million |
| Net Cash Flow | $11.85 Million |
| Net Cash Flow From Operating Activities | $-108.90 Million |
| Net Cash Flow From Financing Activities, Continuing | $299.35 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Diluted Earnings Per Share | $-1.49 |
| Research and Development | $118.28 Million |
| Revenues | $0 |
| Income/Loss From Continuing Operations After Tax | $-124.29 Million |
| Other Operating Expenses | $28.87 Million |
| Basic Earnings Per Share | $-1.49 |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $-122.82 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $1.48 Million |
| Comprehensive Income/Loss | $-122.82 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Current Liabilities | $18.96 Million |
| Wages | $6.18 Million |
| Accounts Payable | $5.65 Million |
| Current Assets | $499.44 Million |
| Equity Attributable To Noncontrolling Interest | $0 |
| Assets | $511.28 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||